Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 26, 2021

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2023

Conditions
Urinary Tract InfectionAcute PyelonephritisHospital Acquired PneumoniaVentilator-associated PneumoniaBacteremiaIntra-abdominal Infection
Interventions
DRUG

Zavicefta, Ceftazidime-Avibactam

CAZ-AVI 2.5 g (2 g ceftazidime + 0.5 g avibactam) administered IV as a 2 hour infusion every 8 hours. Dose adjustments are available for participants with CrCL ≤50 mL/min.

DRUG

Best Available Treatment

main treatment expected to be used as either monotherapy or in combination are colistin, tigecycline, fosfomycin, amikacin, and meropenem

Trial Locations (37)

100191

Peking University Third Hospital, Beijing

200040

Huashan Hospital, Fudan University, Shanghai

200240

Shanghai Fifth People's Hospital, Fudan University, Shanghai

214400

Jiangyin People's Hospital, Jiangyin

Jiangyin People's Hospital, Jiangyin

221006

Affiliated Hospital of Xuzhou Medical University, Xuzhou

225001

Subei People's Hospital of Jiangsu province, Yangzhou

233000

The First Affiliated Hospital of Bengbu Medical, Bengbu

233004

The First Affiliated Hospital of Bengbu Medical College, Bengbu

236000

Fuyang People's Hospital, Fuyang

247000

Chizhou People's Hospital, Chizhou

300222

Tianjin Chest Hospital, Tianjin

310013

Zhejiang Hospital, Hangzhou

310014

Zhejiang Provincial People's Hospital, Hangzhou

317000

Taizhou Hospital of Zhejiang Province, Taizhou

323000

Lishui People's Hospital, Lishui

325035

The 2nd Affiliated Hospital of WMU, Wenzhou

325099

Wenzhou Central Hospital, Wenzhou

330006

Jiangxi Provincial People's Hospital, Nanchang

361004

Zhongshan Hospital Xiamen University, Xiamen

450000

Henan provincial people's hospital, Zhengzhou

450003

Henan provincial people's hospital, Zhengzhou

471009

Luoyang Central Hospital, Luoyang

473000

NanYang central hospital, Nanyang

510180

Guangzhou First People's Hospital, Guangzhou

511518

Qingyuan People's Hospital, Qingyuan

518020

Shenzhen People's Hospital, Shenzhen

518035

The Second People's Hospital of Shenzhen, Shenzhen

524000

Affiliated Hospital of Guangdong Medical University, Zhanjiang

541001

Affiliated Hospital of Guilin Medical College, Guilin

563000

Affiliated Hospital of Zunyi Medical University, Zunyi

610055

Chengdu Xinhua Hospital, Chengdu

650034

The First People's Hospital of Kunming (South Hospital), Kunming

The First people's Hospital of Kunming, Kunming

650224

The First People's Hospital of Kunming Ganmei Hospital (North Hospital), Kunming

071000

Affiliated Hospital of Hebei University, Baoding

014000

Baotou Central Hospital, Baotou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04882085 - Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults | Biotech Hunter | Biotech Hunter